Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Consolidation Durvalumab Should Not Be Administered to Patients With Stage III EGFR-Mutant NSCLC.
Consolidation Durvalumab Should Not Be Administered to Patients With Stage III EGFR-Mutant NSCLC. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer Aredo, J. V., Hellyer, J. A., Neal, J. W., Wakelee, H. A. 2021; 16 (12): 1994-1998View details for DOI 10.1016/j.jtho.2021.07.033
View details for PubMedID 34809803